David Ouyang, MD
@david_ouyang
Cardiologist @CedarsSinai • Co-founder @InVision_AI • Deputy Editor @NEJM_AI • Computer Vision, AI/ML, Data Science
ID: 2301842168
https://intentionalintelligence.substack.com/ 20-01-2014 18:33:01
1,1K Tweet
3,3K Takipçi
988 Takip Edilen
Congrats to the InVision Medical Technology Corporation team! Clear identification of etiologies of HF, particularly HFpEF, is critical for early access and targeted treatment!
Editorial by Robert Avram and William Fearon: AI-RISE to the Challenge — Artificial Intelligence Reduces Time to Treatment in STEMI nejm.ai/4bob3dW #AIinMedicine #Cardiology
Clinical and genetic associations of asymmetric apical and septal left ventricular hypertrophy bit.ly/46HXwNL #EHJDigital #UKBiobank #GWAS Nico Bruining EiC EHJ Digital Health rafavidalperez Gerhard Hindricks HFAPresident
EchoNet-MR is a novel, opensource deep learning algorithm trained on >2 million videos from transthoracic echocardiography for high-throughput mitral regurgitation (MR) assessment Amey Vrudhula @DavidOuyang Cedars-Sinai Academic Medicine Grant Duffy Milos Vukadinovic ahajournals.org/doi/10.1161/CI…
Great article by Mariana Lenharo highlighting the landscape of medical AI. Was a delight to chat with you and brainstorm about the intersection of deployment, regulation, and reimbursement!
Such a fun conversation with Andrew Beam and Arjun (Raj) Manrai! So many friends and interests in common! NEJM AI
🚨 MAJOR news in the #ATTR #amyloidosis world! Today the much-anticipated HELIOS-B results were presented European Society of Cardiology & simultaneously published in NEJM. The largest ATTR-CM trial published to date, testing #vutrisiran vs. placebo. Bottom line: Huge win for vutrisiran!
Strong work lead by chief fellow Rishi K Trivedi, MD PhD!